Navigation Links
Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research
Date:4/3/2008

Long Term Development Agreement to Produce Reference Standard Reagents to

Advance Cancer Research

NEWARK, Del., April 3, 2008 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leader in providing advanced antibody products and services to the life sciences industry announced that it has been selected by Science Applications International Corporation - Frederick (SAIC-F), to develop monoclonal antibodies for the Proteomics Reagents & Resources component of the National Cancer Institute (NCI) Clinical Proteomic Technologies for Cancer initiative (CPTC). The goal of CPTC is to accelerate discovery and clinical research in cancer using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics that identify and minimize experimental variability from run to run, instrument to instrument, and lab to lab. CPTC aims to achieve this through the optimization of existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. The Proteomic Reagents & Resources component will include SOPs, data, proteins, and well-characterized, high-quality antibodies whose performance characteristics will be conducted at an Antibody Characterization Laboratory at NCI-Frederick (NCI-F) that is part of NCI-F's Advanced Technology Program.

SDI was awarded the competitive contract to produce monoclonal antibodies that will serve as reference reagents for the scientific cancer community based on its technical strength, large-scale capacity, standardized processes, and fully integrated quality management system.

Matthew H. Knight, SDI's President and Chief Executive Officer, commented, "SDI is very proud to have been selected to become a key supplier in this large scale initiative. This award is another example of how our commitment to efficiency, quality, capacity, and expertise has positioned us as a premier supplier of comprehensive antibody services to the research community. Being selected to supply these critical tools to advance cancer research is further validation of the exceptional team and infrastructure SDI has developed. As the study of proteins increases in importance to the research community, we foresee a continued and sustained need for SDI's expertise in antibodies as they continue to be the most widely used tools for understanding the molecular dynamics underlying disease."

Under the contract, SDI will produce monoclonal antibodies for the Clinical Proteomic Technologies for Cancer Initiative of the NCI (http://proteomics.cancer.gov) and SAIC-F and the NCI will extensively characterize these reagents consistent with their mission to make available high quality reagents with baseline data.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. (SDI) is an antibody technology company; developing, commercializing and marketing innovative and proprietary biotechnology solutions that preserve and enhance the quality of human health. SDI's antibody division supplies critical reagents used in the diagnosis of disease. The Company's new Genomic Antibody Technology(R) is gaining wide adoption in producing custom research reagents for applied proteomic research, and drug/biomarker discovery among academic, biotech and large pharmaceutical customers. The Company's SEQer(R) antibody catalog is the fastest growing collection of polyclonal antibodies for cancer research. SDI scientists are experts in the development of immunoassays and are using the Company's capacity for high throughput production of high quality antibodies to deliver content for a new generation of multiplex assays for use in biomarker discovery. For more information, visit the Company's website at http://www.sdix.com.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

Company Contact: Investor Contact:

Stan Fronczkowski Hayden Communications

Chief Financial Officer Brett Maas (brett@haydenir.com)

(302) 456-6789 (646) 536-7331

http://www.sdix.com


'/>"/>
SOURCE Strategic Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
2. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
3. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
4. RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
9. Immtech Appoints Blythe Weigh as Strategic Advisor
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):